Gilead Sciences Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Gilead Sciences de 10.1% y 2.4% por año respectivamente. Se prevé que el BPA crezca en un 10.2% al año. Se espera que la rentabilidad financiera sea de 31.9% en 3 años.

Información clave

36.7%

Tasa de crecimiento de los beneficios

36.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.8%
Tasa de crecimiento de los ingresos	2.2%
Rentabilidad financiera futura	33.2%
Cobertura de analistas	Good
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:GIS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	28,722	6,927	10,011	9,954	23
12/31/2025	27,975	6,465	9,418	9,582	27
12/31/2024	27,587	403	8,518	4,950	27
3/31/2024	27,450	485	7,900	8,481	N/A
12/31/2023	27,116	5,665	7,421	8,006	N/A
9/30/2023	27,391	5,876	7,853	8,404	N/A
6/30/2023	27,382	5,484	8,926	9,512	N/A
3/31/2023	27,043	5,583	8,386	8,976	N/A
12/31/2022	27,281	4,592	8,344	9,072	N/A
9/30/2022	27,136	3,334	9,007	9,710	N/A
6/30/2022	27,515	4,137	9,415	10,100	N/A
3/31/2022	27,472	4,515	9,953	10,614	N/A
12/31/2021	27,305	6,225	10,805	11,384	N/A
9/30/2021	27,482	7,394	9,491	10,095	N/A
6/30/2021	26,638	5,162	8,472	9,092	N/A
3/31/2021	25,564	301	8,698	9,342	N/A
12/31/2020	24,689	123	7,518	8,168	N/A
9/30/2020	23,147	1,268	8,160	8,832	N/A
6/30/2020	22,174	-257	8,510	9,227	N/A
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	7,639	8,476	N/A
3/31/2019	22,320	5,892	6,758	7,707	N/A
12/31/2018	22,127	5,455	7,476	8,400	N/A
9/30/2018	22,281	1,587	7,912	8,808	N/A
6/30/2018	23,197	2,208	8,432	9,290	N/A
3/31/2018	24,690	3,464	10,559	11,243	N/A
12/31/2017	26,107	4,628	N/A	11,898	N/A
9/30/2017	27,478	11,601	N/A	12,684	N/A
6/30/2017	28,466	12,213	N/A	14,383	N/A
3/31/2017	29,101	12,637	N/A	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A
9/30/2014	20,696	9,406	N/A	10,524	N/A
6/30/2014	17,437	7,463	N/A	7,233	N/A
3/31/2014	13,669	4,580	N/A	4,001	N/A
12/31/2013	11,202	3,075	N/A	3,105	N/A
9/30/2013	10,585	3,046	N/A	3,084	N/A
6/30/2013	10,229	2,933	N/A	3,076	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.1% al año) de GIS es superior a la tasa de ahorro (0.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (28.2% al año) de GIS crezcan más rápidamente que el mercado German (14.9% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de GIS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2.4% al año) de GIS crezcan más despacio que el mercado de German (5.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.4% al año) de GIS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GIS sea alta dentro de 3 años (31.9%)

Gilead Sciences Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend of US$0.77 announced

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

New minor risk - Financial position

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$1.75 (vs US$1.43 in 3Q 2022)

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Insufficient new directors

Gilead Sciences, Inc. Presents New Data Supporting Sunlenca®? (Lenacapavir) as an Important Treatment Option for Adults with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces New Long-Term Real-World Data from BICSTaR Study Highlighting Safety and Efficacy Profile of Biktarvy as Treatment Regimen for Broad Range of People with HIV, Including Those with Prior Treatment History or Comorbidities

Gilead Sciences, Inc. Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Purpose Program

Gilead Demonstrates the Impact of Global Collaboration in Advancing Hiv Research and Health Equity At EACS 2023

Gilead Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

New minor risk - Financial position

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.84 (vs US$0.91 in 2Q 2022)

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento